DFX Intelligence
Private Credit Intelligence
The capital structure graph behind private markets. Who lent, to whom, under which sponsor, through which facility, how large the piece was, when it matures and what changed, with a filing behind every number. A BDC piece is that BDC's piece, a sum of pieces is a lower bound, and a sponsor is named with the evidence that names it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Borrower
B•••••••• P•••••• I••
Drug Discovery & Developmentgroup grade Aoff every schedule since Sep 30, 2025sponsor A•••••• C•••••• M••••••••• L• carried
Also written as: 2018; 21; 6; Equity
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$12.0M
n/a on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
11
1 on the latest quarter
Facilities
1
2 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Sep 30, 2025
Events
6
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Sep 30, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Sep 30, 2024 | at least $300M | 100c | S+650 bp | Jan 1, 2029 | 11 |
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | equity equity Acquisition Date 6/21/2018, Series Common Stock | n/a | $12.0M 533c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 8 | $300M | $299M | 100c | 0 |
| Jun 30, 2024 | 8 | $225M | $299M | 100c | 0 |
| Mar 31, 2024 | 8 | $225M | $297M | 99c | 0 |
| Dec 31, 2023 | 4 | $169M | $164M | 97c | 0 |
| Sep 30, 2023 | 4 | $97.4M | $94.2M | 97c | 0 |
| Jun 30, 2023 | 1 | $37.9M | $34.0M | 90c | 0 |
| Mar 31, 2023 | 1 | $37.6M | $33.7M | 90c | 0 |
| Dec 31, 2022 | 4 | $135M | $131M | 98c | 0 |
What changed
- Facility left every BDC scheduleSep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Spread changed (observed)Mar 31, 2024
- Maturity extended (observed)Mar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- New lender joined a facilityMar 31, 2024
- Lender left a facilityDec 31, 2023
- Lender left a facilityDec 31, 2023
- Lender left a facilityDec 31, 2023
- Mark recoveredSep 30, 2023
- Lender left a facilitySep 30, 2023
- Marked down across lendersMar 31, 2023
- New borrower on a BDC scheduleDec 31, 2022
Sponsor
- A••••••• C•••••• M••••••••• L•
- the sponsor's own portfolio page lists a company of this nameestimatedathyrium.com"portfolio card on https://athyrium.com/portfolio/: B•••••••• P••••• | Biotechnology Fund IV"
- A•••••• C•••••• M••••••••• L•
- the sponsor's own portfolio page lists a company of this nameestimatedaislingcapital.com"portfolio card on https://www.aislingcapital.com/portfolio: B•••••••• P••••• L•• | NasdaqGS:BBIO | Orphan disease drug platform with a robust portfolio of transformative drug programs that address rar"
Identity
- Group key
- BRIDGEBIO PHARMAderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 11 BDCsderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it